Cardiac Marker Testing Market is predicted to reach USD 10.4 billion at a CAGR of 9.70% during the forecast period 2023-2032

Market Research Future (MRFR) has published on the “Global Cardiac Marker Testing Market”.

The Cardiac Marker Testing market is estimated to register a CAGR of 9.70% during the forecast period of 2024 to 2032.

MRFR recognizes the following companies as the key players in the global Cardiac Marker Testing market— Roche Diagnostics, Abbott Laboratories, Siemens Healthineers, Beckman Coulter, bioMérieux, Ortho Clinical Diagnostics, Bio-Rad Laboratories, Randox Laboratories, Thermo Fisher Scientific, Becton, Dickinson and Company and Other.

Cardiac Marker Testing Market Highlights

The global Cardiac Marker Testing market is accounted to register a CAGR of 9.70% during the forecast period and is estimated to reach USD 10.4 billion by 2032.

The Cardiac Marker Testing market is witnessing growth due to several factors. The increasing prevalence of cardiovascular diseases globally necessitates early and accurate diagnosis, driving demand for cardiac marker testing. Additionally, advancements in testing technologies, such as high-sensitivity assays and point-of-care testing, enhance the efficiency and accuracy of cardiac marker detection. Moreover, rising healthcare expenditure, growing awareness about heart health, and the aging population contribute to the overall expansion of the Cardiac Marker Testing market.

Segment Analysis

The global Cardiac Marker Testing market has been segmented based on Product Type, Biomarker Type, Diseases, and End User.

On the basis of Product Type, the market is segmented into Reagents and Kits and Instruments (Chemiluminescence, Immunofluorescence, ELISA, Immunochromatography). The Reagents and Kits emerged as the dominant product type in the Cardiac Marker Testing Market in 2023 due to their widespread use in laboratory settings. These products offer high sensitivity and specificity in detecting cardiac biomarkers, ensuring accurate diagnosis of cardiovascular conditions. Additionally, the availability of a wide range of reagents and kits catering to various testing needs further solidified their position as the preferred choice among healthcare providers.

Based on Biomarker Type, the global Cardiac Marker Testing market has been segmented into Troponin I and T, Creatine Kinase-MB, Brain Natriuretic Peptide, Myoglobin, High-Sensitivity C-Reactive Protein and Other Cardiac Biomarkers. The Troponin I and T biomarkers secured the largest market share in the Cardiac Marker Testing Market in 2023 due to their high specificity and sensitivity in diagnosing myocardial infarction. They are widely recognized as gold-standard biomarkers for detecting cardiac injury, enabling early intervention and treatment. Additionally, the increasing prevalence of cardiovascular diseases and the growing demand for accurate diagnostic tests further fueled their market dominance.

Based on Diseases, the global Cardiac Marker Testing market has been segmented into Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome, Atherosclerosis, and Ischemia. The Myocardial Infarction Diseases captured the largest market share in the Cardiac Marker Testing Market in 2023 due to their significant prevalence and critical need for accurate diagnosis. Cardiac marker testing plays a pivotal role in the early detection and management of myocardial infarction, driving its widespread adoption. Moreover, the rising incidence of cardiovascular diseases globally further propelled the demand for cardiac marker testing in diagnosing myocardial infarction.

Based on End User, the global Cardiac Marker Testing market has been segmented into Laboratory Testing Facilities (Hospital Labs, Reference Labs, Contract Testing Labs), Point-Of-Care Testing Facilities, and Academic Institutions. The Laboratory Testing Facilities emerged as the leading end users in the Cardiac Marker Testing Market in 2023 due to their comprehensive diagnostic capabilities and established infrastructure for conducting cardiac marker tests. These facilities offer high-throughput testing, accurate results, and access to a wide range of cardiac marker assays, making them the preferred choice for healthcare providers in diagnosing cardiovascular conditions.

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of Cardiac Marker Testing Market Outlook Report

Regional Analysis

The global Cardiac Marker Testing market, based on region, has been divided into North America, Europe, Asia-Pacific, and Rest of the World. North America consists of the US and Canada. The Europe Cardiac Marker Testing market comprises of Germany, France, the UK, Italy, Spain, and the rest of Europe. The Cardiac Marker Testing market in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. The Rest of the World Cardiac Marker Testing market comprises the Middle East, Africa, and Latin America.

North America dominated the Cardiac Marker Testing Market in 2023 due to several factors. These include a high prevalence of cardiovascular diseases, advanced healthcare infrastructure, and extensive adoption of innovative diagnostic technologies. Moreover, strong government initiatives, favorable reimbursement policies, and increasing awareness about heart health contributed to North America's leading position in the Cardiac Marker Testing Market.

Europe secured the second-largest market share in the Cardiac Marker Testing Market in 2023 owing to factors such as a significant burden of cardiovascular diseases, well-established healthcare systems, and increasing adoption of advanced diagnostic techniques. Additionally, growing investments in research and development, coupled with supportive regulatory frameworks, facilitated the widespread availability and adoption of cardiac marker testing in Europe, solidifying its position in the market.

Asia Pacific is experiencing the highest compound annual growth rate (CAGR) in the Cardiac Marker Testing Market due to factors such as the increasing prevalence of cardiovascular diseases, rising healthcare expenditure, expanding access to healthcare services, and growing awareness about the importance of early diagnosis. Additionally, advancements in healthcare infrastructure and the adoption of innovative diagnostic technologies contribute to significant growth potential in Asia Pacific.

Furthermore, the rest of the world's Cardiac Marker Testing market is divided into the Middle East, Africa, and Latin America. The rest of the world growth in the Cardiac Marker Testing market due to factors such as improving healthcare infrastructure, rising prevalence of cardiovascular diseases, and increasing focus on preventive healthcare measures. Additionally, expanding healthcare expenditure and growing investments in diagnostic technologies contribute to market expansion in these regions.

Key Findings of the Study

• The global Cardiac Marker Testing market is expected to reach USD 10.4 billion by 2032, at a CAGR of 9.70% during the forecast period.


• The Asia Pacific region is experiencing rapid growth in the Cardiac Marker Testing market due to factors such as increasing incidence of cardiovascular diseases, rising healthcare investments, expanding access to healthcare services, and growing awareness.


• Based on Diseases, the Myocardial Infarction segment was attributed to holding the largest market in 2023.


• Siemens AG, NEL ASA, ThyssenKrupp, ITM Power, CF Industries Holdings, Inc., Ballard, Roche Diagnostics, Abbott Laboratories, Siemens Healthineers, Beckman Coulter, bioMérieux, Ortho Clinical Diagnostics, Bio-Rad Laboratories, Randox Laboratories, Thermo Fisher Scientific, and Becton, Dickinson and Company are the key market players.